CXCL10 and tuberculosis: Altogether, these data show that the pro-inflammatory chemokine IP-10 can respond with a dynamic pattern to any sort of inflammation underscoring the importance to clinically investigate further patients who experience a non-satisfactory decline in IP-10 due to either treatment failure, TB relapse or intercurrent co-morbidities.